{
    "fund_name": "LS ARK Genomic Revolution Tracker ETP",
    "type": "ETP",
    "ucits": false,
    "replication_method": "physical",
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "complex_factors": [
        "ETP structure with collateralized exposure",
        "No capital protection",
        "High risk indicator (6/7)",
        "Potential for total loss of investment",
        "Complex collateral management structure"
    ],
    "classification": "complex",
    "supporting_data": "The product is classified as complex primarily due to its ETP structure, which involves collateralized exposure to the underlying ARK Genomic Revolution ETF. While the replication method is physical (owning the underlying stock), the ETP structure itself introduces complexity through the collateral management and potential counterparty risk. The high risk indicator (6/7) and the potential for total loss of investment further support this classification. The fact that it's not UCITS-compliant and lacks capital protection also contributes to its complexity. While derivatives are not explicitly mentioned in the documents, the ETP structure with collateral assets introduces elements that may not be easily understood by retail investors.",
    "confidence": 85,
    "counter_argument": "One could argue that since the replication is physical and there's no leverage or derivatives used, the product should be considered non-complex. However, the ETP structure with collateralized exposure and the high risk profile override this argument, as the complexity of the structure and potential risks are significant enough to warrant a complex classification under MiFID II.",
    "risk_level_assessment": "The product's risk profile is high (6/7), which aligns with its complex classification. The potential for total loss of investment and the lack of capital protection further emphasize the high-risk nature of the product."
}